Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvax’s combination therapy uniquely captures the complete antigenic signature of a patient’s own tumor and converts it into a highly stimulatory ‘training program’ for the patient’s immune system. The comprehensive nature of this training is intended to result in both innate and adaptive immune stimulation to optimize long-term anti-tumor effects.
The company’s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer, with additional programs in other types of solid tumors.
Location: United States, Pennsylvania, Philadelphia
Employees: 11-50
Total raised: $135M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Reimagined... | reimagined... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.09.2023 | - | $23M | - |
| 16.07.2020 | Series C | $112M | - |
Mentions in press and media 12
| Date | Title | Description |
| 16.01.2024 | EBCI Brings Awareness to How Newly Diagnosed Glioblastoma Patients Can Access Imvax’s Clinical Study | End Brain Cancer Initiative IMVAX The End Brain Cancer Initiative (EBCI) Brings Awareness to How Newly Diagnosed Glioblastoma Patients Can Access Imvax’s Clinical Study REDMOND, WA, UNITED STATES, January 16, 2024 /EINPresswire.com/ -- The ... |
| 07.09.2023 | Cancer-focused biotech company Imvax raised $23M to advance clinical trials | Cancer-focused biotech company Imvax announced the initial closing of a $23 million fundraising round this week. The Curtis-based firm plans to continue fundraising in the upcoming months. This funding will support Imvax’s Phase 2b clinical... |
| 26.01.2021 | Imvax Announces Publication of Phase 1b Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma in Clinical Cancer Research | |
| 19.10.2020 | Defying predictions of tumult, Philly companies still raked in impressive VC dollars in Q3 | After concern that the coronavirus pandemic would wipe out all chance of venture capital dollars for budding and developing companies this year, the numbers show that in the third quarter of 2020, Philly still received a hearty showing from... |
| 20.07.2020 | These Philly-area Bio and Medtech Companies Raised $116M | Despite the pandemic being very bad for local jobs and a handful of industries, it appears that venture capital continues to be strong throughout the spring and summer. At the beginning of the month, we reported that a handful of Philly are... |
| 20.07.2020 | These Philly-area Bio and Medtech Companies Raised $116M | Despite the pandemic being very bad for local jobs and a handful of industries, it appears that venture capital continues to be strong throughout the spring and summer. At the beginning of the month, we reported that a handful of Philly are... |
| 20.07.2020 | Money Moves: These Philly-area bio and medtech companies raised $116M | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at philly@technical.ly. Despite the pandemic being very bad for local jobs and a handful of industries, it appears that vent... |
| 16.07.2020 | Imvax raises $112M to advance brain cancer cell therapy | Imvax has raised $112 million to take its autologous tumor cell vaccine into a phase 2 glioblastoma multiforme trial. The series C follows phase 1b data on the brain cancer treatment that persuaded existing investors including HP WILD Holdi... |
| 16.07.2020 | Imvax raises $112M to advance brain cancer cell therapy W h i t e p a p e r Weighing the Costs: | Imvax has raised $112 million to take its autologous tumor cell vaccine into a phase 2 glioblastoma multiforme trial. The series C follows phase 1b data on the brain cancer treatment that persuaded existing investors including HP WILD Holdi... |
| 16.07.2020 | Imvax Raises $112M In Series C | Imvax, Inc., a clinical-stage biotechnology company whose groundbreaking personalized neo-antigen immunotherapy, IGV-001, is being studied in patients with glioblastoma multiforme (GBM), and whose proprietary technology has the potential to... |
Show more